Grifols Sees Annual Savings of $230 Million After 2015

(Corrects currency of capital expenditure to dollars after Grifols corrected regulatory filing.)

Grifols SA (GRF) expects to generate annual synergies of $230 million beyond 2015 after its merger with Talecris Biotherapeutics Holdings Corp, the company said in

a presentation filed to regulators today.

Grifols, which holds an investor’s day in Barcelona Oct. 17

and Oct. 18, said total capital expenditure from 2011 to 2015 will be $964 million, while integration costs will be $70 million to 2014, lower than the initial estimate, the company said.

To contact the editor responsible for this story: Emma Ross-Thomas at erossthomas@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.